S100A6 and breast carcinoma: Our data suggest that the lipogenic FASN might be incorporated into the group of metabolic markers specifically enriched by PR-B (but not with those related to the malignant metabolism of cancer stem cells enriched by PR-A) in luminal A-like PR+ breast cancer cells [130–133], likely promoting survival, proliferation, and differentiation.